Patients in the group had various GI cancers including:
• Colon cancer: 48 percent
• Rectal cancer: 42.8 percent
• Esophageal cancer: 10.2 percent
The subgroup of patients who took aspirin had a five-year survival rate of 75 percent, while the patients who did not take aspirin had a five-year survival rate of 40 percent.
More articles on gastroenterology:
FDA approves new CRC drug
Beyond patient care: The biggest challenges in GI
4 GI physicians in the news – Sept. 25, 2015
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.